New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist

Am J Gastroenterol. 2014 Jan;109(1):9-19. doi: 10.1038/ajg.2013.228.

Abstract

The discovery of the first oral anticoagulant, warfarin, was a milestone in anticoagulation. Warfarin's well-known limitations, however, have led to the recent development of more effective anticoagulants. The rapidly growing list of these drugs, however, presents a challenge to endoscopists who must treat patients on these sundry medications. This review is intended to summarize the pharmacological highlights of new anticoagulants, with particular attention to suggested "best-practice" recommendations for the withholding of these drugs before endoscopic procedures.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants* / administration & dosage
  • Anticoagulants* / adverse effects
  • Anticoagulants* / classification
  • Anticoagulants* / pharmacokinetics
  • Blood Loss, Surgical / prevention & control*
  • Drug Interactions
  • Drug Monitoring
  • Endoscopy / adverse effects*
  • Endoscopy / methods
  • Humans
  • Patient Safety
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / classification
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Product Surveillance, Postmarketing
  • Risk Adjustment
  • Thromboembolism / drug therapy*
  • Withholding Treatment

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors